ObsEva Annual Report 2021

Rhea-AI Summary

ObsEva SA has published its Annual Report 2021 to Shareholders on March 31, 2022. The report details the company’s progress in developing therapies aimed at improving women’s reproductive health and pregnancy. ObsEva is focused on treating uterine fibroids, endometriosis, and preterm labor, bolstered by a late-stage clinical pipeline. The report is accessible on their website. For additional inquiries, the CEO and investor contacts are provided.

Positive

• Published Annual Report 2021 detailing company progress.
• Established late-stage clinical pipeline focused on women's reproductive health.

Negative

• None.

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange

 

Geneva, Switzerland and Boston, MA – March 31, 2022 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today published its Annual Report 2021 to Shareholders.

The Annual Report 2021 to Shareholders may be found in the financial section of the Company's website, [here]. To access the Annual Report 2021 to Shareholders directly, please click [here].

About ObsEva

ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on new therapies for the treatment of uterine fibroids, endometriosis, and preterm labor. ObsEva is listed on the Nasdaq Global Select Market and is traded under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is traded under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.

 

For further information, please contact:

CEO Office Contact:
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550

Investor Contact:
Katja Bührer
Katja.buhrer@obseva.com
+1 (917) 969-3438

 

###

 

 

 

Attachment

• Press Release in Pdf

FAQ

What date did ObsEva publish its Annual Report 2021?

ObsEva published its Annual Report 2021 on March 31, 2022.

What is the focus of ObsEva's clinical pipeline?

ObsEva's clinical pipeline focuses on therapies for uterine fibroids, endometriosis, and preterm labor.

Where can I find ObsEva's Annual Report 2021?

ObsEva's Annual Report 2021 can be found on the financial section of their website.

What is ObsEva's stock ticker symbol?

ObsEva's stock ticker symbol is OBSV, traded on NASDAQ.